Protara Therapeutics (TARA) Accumulated Expenses (2013 - 2026)

Protara Therapeutics' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $3.6 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 2.52% year-over-year to $3.6 million; the TTM figure through Mar 2026 stood at $3.6 million (up 2.52% YoY), while the FY2025 annual figure was $3.3 million, up 19.23% from the prior year.
• Accumulated Expenses was $3.6 million for Q1 2026 at Protara Therapeutics, up from $3.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.6 million in Q1 2026 to a low of $936000.0 in Q2 2023.
• Historically, Accumulated Expenses has averaged $2.4 million across 5 years, with a median of $2.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 220.09% in 2022, then plunged 57.76% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $3.2 million in 2022, then slipped by 15.6% to $2.7 million in 2023, then rose by 0.29% to $2.7 million in 2024, then rose by 19.23% to $3.3 million in 2025, then rose by 11.02% to $3.6 million in 2026.
• The last three Accumulated Expenses figures came in at $3.6 million (Q1 2026), $3.3 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.